Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 30, 2026

Orchid Island ORC Q4 2025 Earnings Call Transcript

View original at finance.yahoo.com
Orchid Island ORC Q4 2025 Earnings Call Transcript Image source: The Motley Fool. DATE Friday, Jan. 30, 2026 at 10 a.m. ET CALL PARTICIPANTS Chairman, Chief Executive Officer, and President — Robert E…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Expense ratio trending asymptotically toward 1% with scale, comparable to substantially larger peers

    80% confidence
  • Prepayment speeds expected to moderate modestly, improving carry. Current high speeds of 50-60 CPR in rolls are inconsistent with rate outlook

    80% confidence
  • Debate exists on whether GSE announcement represents actual increase in MBS purchases versus current run rate

    80% confidence
  • If no Fed cuts are expected, 2-year yield should rise from 3.54% and 10-year could move to 4.50%+ from 4.25%, pushing mortgage rates to borrowers to 6.5-7%

    80% confidence
  • Current MBS spreads are at tightest levels since 2013 taper tantrum through COVID period, with current coupon mortgage to 10-year Treasury at 80-90bp compared to historic range of approximately 75bp

    80% confidence
  • Mortgages could tighten further despite already tight levels, with potential for GSEs to remain or become more active

    80% confidence
  • Economic data during Q4 was suspect due to government shutdown on October 1 and delayed/suspect data after government reopening

    80% confidence
  • Portfolio positioned for flat rates and defensively for bear steepening scenario, with focus on hedging inflation reignition

    80% confidence
  • Company doubled in size during 2025 with equity and total assets up more than 100%

    80% confidence
  • Swaption volatility declined throughout Q4 and into 2026 to levels comparable to Fed QE rate suppression regime from 10+ years ago

    80% confidence
  • Current book value as of call date is up approximately 1.6% including dividend accrual

    80% confidence
  • Spread to borrower remains at approximately 200bp over 10-year Treasury and has not tightened as much as MBS spreads

    80% confidence
  • Investment grade corporate spreads at or near tightest levels since late 1990s, with high yield spreads also tight

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com